On the Record · Lantheus Holdings

Lantheus Holdings acquisitions, on the record

The businesses Lantheus Holdings bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
Cerveau Technologies, Inc. Word for word“On February 6, 2023, the Company acquired Cerveau and made an upfront payment of approximately $35.3 million to the Selling Stockholders.” 10-K for 2023	acquisition	February 6, 2023	—
RELISTOR royalty asset (RELISTOR licensed intangible asset associated with net sales royalties) Word for word“On August 2, 2023, we sold the right to our RELISTOR net sales royalties, which is classified as a licensed intangible asset (“RELISTOR royalty asset”), under our license agreement with Bausch; we retained the rights to future sales-based milestone payments.” 10-K for 2023	divestiture	August 2, 2023	—
Somerset, NJ radiopharmaceutical manufacturing facility and related assets (to Perspective Therapeutics, Inc.) Word for word“In addition, Perspective agreed to acquire the assets and associated lease of our radiopharmaceutical manufacturing facility in Somerset, New Jersey, subject to customary closing conditions, including regulatory approval.” 10-K for 2023	agreed divestiture	—	—
Perspective Therapeutics, Inc. common stock (up to 19.9% of outstanding shares) Word for word“On January 22, 2024, following the satisfaction of applicable closing conditions, our subsidiary, Lantheus Alpha, purchased 56,342,355 shares of Perspective’s common stock at a purchase price of $0.37 per share in a private placement transaction.” 10-K for 2023	agreed acquisition	January 22, 2024	—
Life Molecular Imaging Ltd. Word for word“On January 13, 2025, we announced that we entered into a definitive agreement to acquire Life Molecular.” 10-K for 2024	agreed acquisition	January 13, 2025	—
RM2 assets from Life Molecular Word for word“For more information on the acquisition of the global rights to RM2, see Note 21, “Acquisition of Assets” to our consolidated financial statements included in Part II, Item 8, “Financial Statements and Supplementary Data” of this Form 10-K.” 10-K for 2024	acquisition	—	—
Evergreen Theragnostics, Inc. Word for word“Pursuant to the Evergreen Merger Agreement, we will pay an upfront amount of $250 million, payable in cash at closing and subject to customary adjustments as set forth in the Evergreen Merger Agreement, and milestone payments in an aggregate additional cash amount of up to $752.5 million upon the occurrence of certain Milestone Trigger Events (as set forth in the Evergreen Merger Agreement).” 10-K for 2024	agreed acquisition	—	an upfront amount of $250 million
Meilleur Technologies, Inc. Word for word“On June 18, 2024, we acquired Meilleur Technologies, Inc. (“Meilleur”), including its asset NAV-4694, an investigational F-18-PET imaging agent that targets beta amyloids in Alzheimer’s disease.” 10-K for 2024	acquisition	June 18, 2024	—
Radiopharm Theranostics Limited licensed preclinical assets Word for word“On June 15, 2024, we entered into an agreement with Radiopharm to acquire all of Radiopharm’s global, exclusive rights to two licensed preclinical assets for an upfront payment of $2.0 million (the “Radiopharm Asset Purchase”).” 10-K for 2024	acquisition	June 15, 2024	an upfront payment of $2.0 million
RELISTOR net sales royalties Word for word“On August 2, 2023, we sold the right to our RELISTOR net sales royalties, which is classified as a licensed intangible asset (“RELISTOR royalty asset”), under our license agreement with Bausch Health Companies, Inc.” 10-K for 2024	divestiture	August 2, 2023	—
SPECT business Word for word“On January 1, 2026, we completed the sale of our single-photon emission computerized tomography (“SPECT”) business to SHINE Technologies, LLC (“SHINE”), a wholly-owned subsidiary of Illuminated Holdings, Inc., for total consideration of up to $155.0 million, consisting of cash, a convertible installment note, a term note and contingent earnout payments.” 10-K for 2025	divestiture	On January 1, 2026	up to $155.0 million
Evergreen Theragnostics, Inc. Word for word“As consideration for the Evergreen Merger, we made an upfront payment of $276.4 million in cash.” 10-K for 2025	merger	—	$276.4 million
Meilleur Word for word“On June 18, 2024, we acquired Meilleur, including its asset NAV-4694, an investigational late-stage F-18-labeled PET imaging agent that targets beta amyloids in Alzheimer’s disease.” 10-K for 2025	acquisition	On June 18, 2024	—

As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year ended	Goodwill from acquisitions
2020-12-31	$42.9 million
2021-12-31	$2.6 million
2022-12-31	$0

Deal filings since 2016

2026-08-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-07-22 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2025-04-01 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2025-01-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-01-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-12-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-05-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-12-20 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2022-12-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-12-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-11-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-06-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-06-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-06-22 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2020-04-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-02-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-11-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-10-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-07-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-01-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-06-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-05-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-04-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-03-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-03-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-11-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-09-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-09-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-08-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-08-11 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2016-01-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-01-13 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets

Read from Lantheus Holdings’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.